Immunoprofiling for advanced biomarker discovery
Sengenics at a glance
Sengenics is a one-of-a-kind immuneproteomics company that leverages its patented KREX™ technology for production of full-length, correctly folded, and functional proteins. The technology is used to support pharma and academic research to advance precision medicine through an increased understanding of the autoimmune response in humans. Sengenics is currently focused on measurement of autoantibodies for applications in autoimmune diseases, oncology, neurological conditions, and infectious disease.
- Year acquired
- 2020
- Sector
- Life science
- Employees
- 45
- Website
- https://www.sengenics.com
- Investment theme
- Changing Demographics
- Contact
- christoph.waer@summaequity.com
Key developments in 2023
In 2023, the company dedicated itself to establishing a solid foundation for growth and honing its strategic direction. It took impressive strides in accelerating its path to expansion, fine-tuning its strategic vision, and incorporating crucial capabilities to propel the company forward. Notably, earlier in the year, the company unveiled its groundbreaking i-Ome Discovery functional protein microarray, marking a significant milestone in its journey.
What are the challenges Sengenics addresses
-
80%
of patients receive no benefit from treatment with the top 10 best-selling drugs in the world
-
9.2%
of OECD GDP is spent on healthcare
How does Sengencis help?
Reality today
We do not understand the biology of many leading diseases and lack appropriate biomarkers, preventing us from developing effective medication and delivering precision treatment.
Sengencis approach
Sengenics proteomics technology enables biological response research at unrivalled sensitivity and specificity, helping develop more targeted, effective, and efficient diagnostics and therapies.
Aspirational future
Deeper understanding of human biology and disease allows us to develop and deliver the most effective diagnostics and treatments for patients.
Who is impacted?
Researchers are impacted directly through more effective tools to understand human biology and more effective drug development. Patients are impacted indirectly through breakthroughs in treatments.
Contribution
Sengenics unique technology and collaborative partnerships with top biopharma companies contributes to the advancement of research on how to develop more targeted, effective and efficient diagnostics and therapies.
Risks
Sengenics impact depends in part on how its customers in biopharma choose to use its tools. Product quality is also fundamentally important, enabling reproducibility in research and precise, safe innovation in therapies.
